Clinical significance of serum lipids in idiopathic pulmonary alveolar proteinosis

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Fang, Cun S ^a   Wang, Ying C ^a   Zhang, Tao H ^a   Wu, Jing ^a   Wang, Wei ^a   Wang, Chun ^a   Zhang, Ming Y ^a  

^a NANJING CHEST HOSPITAL   (China)

Author keywords

high density lipoprotein cholesterol lipid; low density lipoprotein cholesterol; pulmonary alveolar proteinosis; whole lung lavage

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTATE DEHYDROGENASE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; LIPID; OXYGEN;

ADULT; ARTERIAL CARBON DIOXIDE TENSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FATTY LIVER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LIPID BLOOD LEVEL; LUNG ALVEOLUS PROTEINOSIS; LUNG FUNCTION TEST; LUNG LAVAGE; MALE; OCCUPATIONAL EXPOSURE; OXYGEN TENSION; PNEUMONIA; RETROSPECTIVE STUDY; REVIEW; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; TUBERCULOSIS; ARTICLE; BLOOD; BLOOD GAS ANALYSIS; CASE CONTROL STUDY; LIPID METABOLISM; MIDDLE AGED;

ADULT; BIOLOGICAL MARKERS; BLOOD GAS ANALYSIS; BRONCHOALVEOLAR LAVAGE; CASE-CONTROL STUDIES; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; OXYGEN; PULMONARY ALVEOLAR PROTEINOSIS;

EID: 84855789628     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-12     Document Type: Review

References (26)

1. Pulmonary Alveolar Proteinosis Progress in the First 44 Years. Seymour JF, Presneill JJ, Am J Respir Crit Care Med 2002 166 215 235 10.1164/rccm.2109105 12119235 (Pubitemid 34765459)
2. GM-CSF pathway correction in pulmonary alveolar proteinosis. Antoniu SA, Expert Opin Biol Ther 2010 10 9 1357 1365 10.1517/14712598.2010.510507 20695835
3. Pulmonary alveolar proteinosis: a bench-to-bedside story of granulocyte-macrophage colony-stimulating factor dysfunction. Greenhill SR, Kotton DN, Chest 2009 136 2 571 577 10.1378/chest.08-2943 19666756
4. The role of lipids in pulmonary surfactant. Veldhuizen R, Nag K, Orgeig S, Possmayer F, Biochim Biophys Acta 1998 1408 (2 3):90-108
5. Serum cholestenoic acid as a potential marker of pulmonary cholesterol homeostasis: increased levels in patients with pulmonary alveolar proteinosis. Steve Meaney, Bonfield TL, Hansson M, Babiker A, Kavuru MS, Thomassen MJ, J Lipid Res 2004 45 2354 2360 10.1194/jlr.M400302-JLR200 15466366 (Pubitemid 39602983)
6. Impaired lipid metabolism in idiopathic pulmonary alveolar proteinosis. Tian X, Luo J, Xu KF, Wang L, Zhou J, Feng R, Gui Y, Wang J, Xu W, Xiao Y, et al. Lipids Health Dis 2011 10 54 10.1186/1476-511X-10-54 21486485
7. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ, Stoller JK, Am J Respir Crit Care Med 2000 161 4 Pt 1 1143 1148 10764303 (Pubitemid 30243821)
8. Whole-lung lavage for pulmonary alveolar proteinosis. Michaud G, Reddy C, Ernst A, Chest 2009 136 6 1678 1681 10.1378/chest.09-2295 19995769
9. Therapy options in pulmonary alveolar proteinosis. Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell BC, Ther Adv Respir Dis 2010 4 4 239 248 10.1177/1753465810378023 20647242
10. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Shah PL, Hansell D, Lawson PR, Reid KB, Morgan C, Thorax 2000 55 1 67 77 10.1136/thorax.55.1.67 10607805 (Pubitemid 30248782)
11. Impact of lung transplantation on serum lipids in COPD. Reed RM, Hashmi S, Eberlein M, Iacono A, Netzer G, Defilippis A, Girgis RE, Toth PP, Scharf S, Jones S, Respir Med 2011
12. [Prevalence of hypertension and glucose/lipid metabolism disorders in 4960 inpatients with chronic obstructive pulmonary disease during 2000-2010]. Cui H, Wei ZM, Cai JF, Li Y, Fan L, Hu YX, Liu L, Zhang M, Liu AM, Nan Fang Yi Ke Da Xue Xue Bao 2011 31 9 1498 1503 21945752
13. Ameliorating effect of capsaicin on alterations in lipid metabolism during mice lung carcinoma. Anandakumar P, Jagan S, Kamaraj S, Ramakrishnan G, Clara JB, Pathitha D, Kavitha T, Devaki T, Arch Pharm Res 2009 32 2 229 234 10.1007/s12272-009-1140-2 19280153
14. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment. Gallego-Ortega D, Ramirez de Molina A, Ramos MA, Valdes-Mora F, Barderas MG, Sarmentero-Estrada J, Lacal JC, PLoS One 2009 4 11 7819 10.1371/journal.pone.0007819 19915674
15. Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Vikstedt R, Ye D, Metso J, Hildebrand RB, Van Berkel TJ, Ehnholm C, Jauhiainen M, Van Eck M, Arterioscler Thromb Vasc Biol 2007 27 3 578 586 10.1161/01.ATV.0000254815.49414.be 17170377
16. Role of phospholipid transfer protein in high-density lipoprotein- mediated reverse cholesterol transport. Yazdanyar A, Yeang C, Jiang XC, Curr Atheroscler Rep 2011 13 3 242 248 10.1007/s11883-011-0172-5 21365262
17. Cholesterol accumulation is increased in macrophages of phospholipid transfer protein-deficient mice: normalization by dietary alpha-tocopherol supplementation. Ogier N, Klein A, Deckert V, Athias A, Bessede G, Le Guern N, Lagrost L, Desrumaux C, Arterioscler Thromb Vasc Biol 2007 27 11 2407 2412 10.1161/ATVBAHA.107.151753 17717294 (Pubitemid 350203957)
18. Elemental analysis of lung tissue particles and intracellular iron content of alveolar macrophages in pulmonary alveolar proteinosis. Shimizu Y, Matsuzaki S, Dobashi K, Yanagitani N, Satoh T, Koka M, Yokoyama A, Ohkubo T, Ishii Y, Kamiya T, et al. Respir Res 2011 12 88 10.1186/1465-9921-12-88 21718529
19. Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages. Trapnell BC, Carey BC, Uchida K, Suzuki T, Curr Opin Immunol 2009 21 5 514 521 10.1016/j.coi.2009.09.004 19796925
20. Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Trapnell BC, Whitsett JA, Annu Rev Physiol 2002 64 775 802 10.1146/annurev.physiol.64.090601.113847 11826288 (Pubitemid 34259249)
21. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Venkateshiah SB, Yan TD, Bonfield TL, Thomassen MJ, Meziane M, Czich C, Kavuru MS, Chest 2006 130 1 227 237 10.1378/chest.130.1.227 16840407 (Pubitemid 44116865)
22. Potent cholesterol-lowering effect by human granulocyte-macrophage colony-stimulating factor in rabbits. Possible implications of enhancement of macrophage functions and an increase in mRNA for VLDL receptor. Ishibashi T, Yokoyama K, Shindo J, Hamazaki Y, Endo Y, Sato T, Takahashi S, Kawarabayasi Y, Shiomi M, Yamamoto T, et al. Arterioscler Thromb 1994 14 10 1534 1541 10.1161/01.ATV.14.10.1534 7918302
23. GM-CSF regulates protein and lipid catabolism by alveolar macrophages. Yoshida M, Ikegami M, Reed JA, Chroneos ZC, Whitsett JA, Am J Physiol Lung Cell Mol Physiol 2001 280 3 379 386 11159019
24. Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Seymour JF, Doyle IR, Nakata K, Presneill JJ, Schoch OD, Hamano E, Uchida K, Fisher R, Dunn AR, Thorax 2003 58 3 252 257 10.1136/thorax.58.3.252 12612307 (Pubitemid 36308005)
25. Differences in the immunolocalization of surfactant protein (SP)-A, SP-D, and KL-6 in pulmonary alveolar proteinosis. Kobayashi M, Takeuchi T, Ohtsuki Y, Pathol Int 2008 58 3 203 207 10.1111/j.1440-1827.2007.02212.x 18251786 (Pubitemid 351190177)
26. Surfactant protein A is a principal and oxidation-sensitive microbial permeabilizing factor in the alveolar lining fluid. Kuzmenko AI, Wu H, Wan S, McCormack FX, J Biol Chem 2005 280 27 25913 25919 10.1074/jbc.M411344200 15890661 (Pubitemid 40962304)